BriaCell Therapeutics Corp 40-F, filed Oct 29, 2021
BriaCell Therapeutics Corp. (BCTX)
About this 40-F
BriaCell Therapeutics Corp filed this 40-F on October 29, 2021, covering the fiscal year ended July 31, 2021.
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM 40-F
| ☐ | Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 |
|---|
or
| ☒ | Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 |
|---|
| For the fiscal year ended: | July 31, 2021 | Commission File Number: | 001-40101 |
|---|
BRIACELLTHERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
| British<br> Columbia, Canada | 2834 | 47-1099599 |
|---|---|---|
| (Province<br> or Other Jurisdiction of<br><br> <br>Incorporation<br> or Organization) | (Primary<br> Standard Industrial Classification<br><br> <br>Code<br> Number) | (I.R.S.<br> Employer<br><br> <br>Identification<br> No.) |
Suite 300 – 235 15^th^ Street
West Vancouver, British Columbia V7T 2X1
Canada
(604) 921-1810
(Address and telephone number of registrant’s principal executive offices)
ParacorpIncorporated
2804Gateway Oaks Drive #100,
Sacramento,CA 95833
Telephone:(888) 280-6563
(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)
| Copies<br> to:<br><br> <br>Gregory Sichenzia, Esq.<br><br> <br>Avital Perlman, Esq.<br><br> <br>Sichenzia Ross Ference LLP<br><br> <br>1185 Avenue of Americas<br><br> <br>31^st^Floor<br><br> <br>New York, NY 10036<br><br> <br>Telephone: (212) 930-9700<br><br> <br>Facsimile:(212) 930-9725 | Copies<br> to:<br><br> <br>Aaron Sonshine<br><br> <br>Bennett Jones LLP<br><br> <br>3400 One First Canadian Place<br><br> <br>P.O. Box 130, Toronto, ON<br><br> <br>M5X 1A4<br><br> <br>Telephone: (416) 777-6448<br><br> <br>Facsimile:(416) 863-1716 |
|---|
Securities registered or to be registered pursuant to Section 12(b) of the Act:
| Title<br> of Each Class: | Trading<br> Symbol | Name<br> of Each Exchange On Which Registered: |
|---|---|---|
| Common<br> Shares, no par value<br><br> <br>Warrants<br> to purchase common shares, no par value | BCTX<br><br> <br>BCTXW | NASDAQ<br> Capital Market;<br><br> <br>NASDAQ<br> Capital Market |
Securities registered or to be registered pursuant to Section 12(g) of the Act: Not applicable
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: Not applicable For annual reports, indicate by check mark the information filed with this form:
| ☒<br> Annual Information Form | ☒<br> Audited Annual Financial Statements |
|---|
Indicate the number of outstanding shares of each of the registrant’s classes of capital or common stock as of the close of the period covered by the annual report: As of July 31, 2021, there were 15,269,583 common shares outstanding.
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the Registrant was required to submit such files). ☒ Yes ☐ No
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ☒
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
DOCUMENTS INCORPORATED BY REFERENCE
The following documents of BriaCell Therapeutics Corp. (the “Registrant” or the “Company”) are filed as exhibits to this Annual Report and are hereby incorporated by reference herein:
| ● | the<br> Registrant’s Annual Information Form for the year ended July 31, 2021; |
|---|---|
| ● | the<br> Registrant’s Audited Consolidated Financial Statements for the years ended July 31, 2021 and 2020, including the notes thereto,<br> together with the report of the independent registered public accounting firm thereon; and |
| ● | the<br> Registrant’s Management’s Discussion and Analysis for the year ended July 31, 2021. |
EXPLANATORY NOTE
The Company is a Canadian issuer eligible to file its annual report pursuant to Section 13 of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”) on Form 40-F. The Company is a “foreign private issuer” as defined in Rule 3b-4 under the Exchange Act and Rule 405 under the Securities Act of 1933, as amended. Accordingly, the Company’s equity securities are exempt from Sections 14(a), 14(b), 14(c), 14(f) and 16 of the Exchange Act pursuant to Rule 3a12-3.
The Company is permitted, under a multi-jurisdictional disclosure system adopted by the United States, to prepare this Annual Report on Form 40-F in accordance with Canadian disclosure requirements, which are different from those of the United States.
The Company prepares its financial statements in accordance with International Financial Reporting Standards as issued by the International Financial Accounting Boards, and they may be subject to Canadian auditing and auditor independence standards. Accordingly, the financial statements of the Company incorporated by reference in this Annual Report may not be comparable to financial statements of United States companies.
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This Annual Report contains forward-looking statements that relate to the Company’s current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “may”, “might”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “indicate”, “seek”, “believe”, “predict” or “likely”, or the negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy and financial needs. A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking statements in this Annual Report and corresponding Annual Information Form (“AIF”), including, but not limited to, the following material factors:
| ● | a<br> history of operating losses; |
|---|---|
| ● | early<br> stages of development; |
| ● | lack<br> of supporting clinical data; |
| ● | unproven<br> market; |
| ● | ability<br> to manage growth; |
| ● | reliance<br> on third parties; |
| ● | pre-clinical<br> studies and initial clinical trials are not necessarily predictive of future results; |
| ● | raw<br> materials and product supply; |
| ● | the<br> need for additional capital and access to capital markets; |
| ● | dependence<br> on key personnel; |
| ● | unsuccessful<br> acquisitions; |
| ● | data<br> security breaches; |
| ● | ability<br> to continue as a going concern; |
| ● | manufacturing,<br> pharmaceutical development, marketing capability, and commercialization; |
| ● | litigation<br> related to product liability; |
| ● | business<br> disruptions due to Covid-19; |
| ● | developing,<br> maintaining and protecting proprietary technologies; |
| ● | intellectual<br> property and litigation to protect it; |
| ● | competition; |
| ● | governmental<br> regulation; |
| ● | operation<br> in foreign jurisdictions; |
| ● | volatility<br> in price and liquidity of the Company’s securities; |
| ● | dilution; |
| ● | difficulty<br> in raising future capital; |
| ● | the<br> Company’s status as an Emerging Growth Company and a Foreign Private Issuer; |
| ● | concentrated<br> voting control; |
| ● | becoming<br> classified as a passive foreign investment company; |
| ● | additional<br> financings; |
| ● | adverse<br> reports by business analysts; |
| ● | legislation<br> delaying or preventing a change in control; and |
| ● | difficulty<br> enforcing civil liabilities. |
Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, any investors or users of this document should not place undue reliance on these forward-looking statements.
Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors described in the Annual Information Form incorporated by reference in this Annual Report.
The forward-looking statements made in this Annual Report relate only to events or information as of the date of this Annual Report and are expressly qualified in their entirety by this cautionary statement. Except as required by law, we do not assume any obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Annual Report, including the occurrence of unanticipated events. An investor should read this Annual Report with the understanding that our actual future results may be materially different from what we expect.
DISCLOSURE CONTROLS AND PROCEDURES
The required disclosure is included in Management’s Discussion and Analysis, which is incorporated herein by reference to Exhibit 99.2.
MANAGEMENT’S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
This annual report does not include a report of management’s assessment regarding internal control over financial reporting due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.
CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING
During the period covered by this Annual Report, no changes occurred in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
NOTICES PURSUANT TO REGULATION BTR
There were no notices required by Rule 104 of Regulation BTR that the Company sent during the year ended July 31, 2021 concerning any equity security subject to a blackout period under Rule 101 of Regulation BTR.
AUDIT COMMITTEE AND AUDIT COMMITTEE FINANCIAL EXPERT
The Board has a separately designated standing audit committee (the “Audit Committee”) established for the purpose of overseeing the accounting and financial reporting processes of the Company and audits of the financial statements of the Company in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (“Exchange Act”). As of the date of this Annual Report, the Company’s Audit Committee is comprised of Vaughn C. Embro-Pantalony, Martin Schmieg and Dr. Rebecca Taub, and chaired by Mr. Embro-Pantalony. Our Board has determined that each of Mr. Schmieg and Mr. Embro-Pantalony is financially literate and meets the independence requirements for directors, including the heightened independence standards for members of the audit committee under Rule 10A-3 under the Exchange Act and National Instrument (“NI”) 52-110 from the Ontario Securities Commission. Our Board has determined that Mr. Embro-Pantalony is “financially sophisticated” within the meaning of the Nasdaq Rules, “financially literate” within the meaning of NI 52-110, and a “financial expert” as defined by Rule 10A-3 under the Exchange Act and as defined in paragraph (8)(b) of General Instruction B of Form 40-F.
CODE OF ETHICS
The Board has not adopted a formal written Code of Business Conduct and Ethics. However, the small size of the Board and number of officers and employees allows the Board to monitor on an ongoing basis the activities of management and to ensure that the highest standard of ethical conduct is maintained. The Board views good corporate governance as an integral component to its success and to meet its responsibilities to shareholders. As the Company grows in size and scope, the Board anticipates that it will formulate and implement a formal Code of Business Conduct and Ethics.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
The required disclosure is included in the Annual Information Form, under the heading “External Audit Service Fees,” which is incorporated herein by reference to Exhibit 99.3.
OFF-BALANCE SHEET ARRANGEMENTS
The required disclosure is included under the heading “Off Balance Sheet Arrangements” in Management’s Discussion and Analysis, which is incorporated herein by reference to Exhibit 99.2.
CONTRACTUAL OBLIGATIONS
The required disclosure is included under the heading “Commitments” in Management’s Discussion and Analysis, which is incorporated herein by reference to Exhibit 99.2.
NASDAQ CORPORATE GOVERNANCE
The rules of the Nasdaq Stock Market LLC (the “Nasdaq Rules”) include certain accommodations in the corporate governance requirements that allow foreign private issuers, such as us, to follow “home country” corporate governance practices in lieu of the otherwise applicable corporate governance standards of the Nasdaq. The application of such exceptions requires that we disclose any significant ways in which our corporate governance practices differ from the Nasdaq Rules that we do not follow. We intend to continue to follow Canadian corporate governance practices in lieu of the requirement under Rule 5620(c) of the Nasdaq Rules that a company’s articles of incorporation provide for a quorum for any meeting of the holders of the company’s common shares that is not less than 33 1/3% of the outstanding common shares of the company. Our notice of articles and articles provide that a quorum of shareholders is constituted by the holders of at least 5% of the shares entitled to vote at the meeting, present in person or represented by proxy, and at least two persons entitled to vote at the meeting, present in person or represented by proxy. In addition, we do not intend to follow Rule 5635 of the Nasdaq Rules that requires that shareholder approval be required for the Company to issue securities in connection with certain events, such as the acquisition of shares or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, rights issues at or below market price, certain private placements, directed issues at or above market price and issuance of convertible notes. Neither Canadian securities laws nor British Columbia corporate law require shareholder approval for such transactions, except where such transactions constitute a “related party transaction” or “business combination” under Canadian securities laws or where such transaction is structured in a way that requires shareholder approval under the Business Corporations Act (British Columbia) , or where the TSX Venture Exchange requires the shareholder approval for the establishment of or amendments to equity-based compensation plans, in which case, we intend to follow our home country requirements.
UNDERTAKING
The Company undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the securities registered pursuant to Form 40-F; the securities in relation to which the obligation to file an annual report on Form 40-F arises; or transactions in said securities.
CONSENT TO SERVICE OF PROCESS
The Company has previously filed with the Commission a written consent to service of process on Form F-X. Any change to the name or address of the Company’s agent for service shall be communicated promptly to the Commission by amendment to the Form F-X referencing the file number of the Company.
EXHIBIT INDEX
The following documents are being filed with the Commission as exhibits to this Annual Report on Form 40-F.
* Previously filed with the SEC
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this Annual Report to be signed on its behalf by the undersigned, thereto duly authorized.
| BRIACELL<br> THERAPEUTICS CORP. | ||
|---|---|---|
| Date:<br> October 29, 2021 | /s/ Dr. William Williams | |
| Name: | Dr. William V. Williams | |
| Title: | President and Chief Executive Officer |
EXHIBIT99.4
CERTIFICATIONOF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEYACT OF 2002
I, Dr. William V. Williams, Chief Executive Officer of BriaCell Therapeutics Corp., certify that:
| 1 | I<br> have reviewed this Annual Report on Form 40-F for the year ended July 31, 2021 of BriaCell Therapeutics Corp., | |
|---|---|---|
| 2 | Based<br> on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary<br> to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to<br> the period covered by this report; | |
| 3 | Based<br> on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material<br> respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in<br> this report; | |
| 4 | The<br> registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures<br> (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange<br> Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
| a. | Designed<br> such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,<br> to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others<br> within those entities, particularly during the period in which this report is being prepared; | |
| b. | Designed<br> such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our<br> supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements<br> for external purposes in accordance with generally accepted accounting principles; | |
| c. | Evaluated<br> the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about<br> the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;<br> and | |
| d. | Disclosed<br> in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s<br> most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Quarterly Report) that has materially<br> affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and | |
| 5 | The<br> registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over<br> financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or<br> persons performing the equivalent functions): | |
| a. | All<br> significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are<br> reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;<br> and | |
| b. | Any<br> fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s<br> internal control over financial reporting. | |
| Date:<br> October 29, 2021 | By: | /s/ William V. Williams |
| --- | --- | --- |
| Dr.<br> William V. Williams | ||
| Chief<br> Executive Officer |
EXHIBIT99.5
CERTIFICATIONOF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEYACT OF 2002
I, Gadi Levin, Chief Financial Officer of BriaCell Therapeutics Corp., certify that:
| 1 | I<br> have reviewed this Annual Report on Form 40-F for the year ended July 31, 2021 of BriaCell Therapeutics Corp., | |
|---|---|---|
| 2 | Based<br> on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary<br> to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to<br> the period covered by this report; | |
| 3 | Based<br> on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material<br> respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in<br> this report; | |
| 4 | The<br> registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures<br> (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange<br> Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
| a. | Designed<br> such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,<br> to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others<br> within those entities, particularly during the period in which this report is being prepared; | |
| b. | Designed<br> such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our<br> supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements<br> for external purposes in accordance with generally accepted accounting principles; | |
| c. | Evaluated<br> the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about<br> the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;<br> and | |
| d. | Disclosed<br> in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s<br> most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Quarterly Report) that has materially<br> affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and | |
| 5 | The<br> registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over<br> financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or<br> persons performing the equivalent functions): | |
| a. | All<br> significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are<br> reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;<br> and | |
| b. | Any<br> fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s<br> internal control over financial reporting. | |
| Date:<br> October 29, 2021 | By: | /s/ Gadi Levin |
| --- | --- | --- |
| Gadi<br> Levin | ||
| Chief<br> Financial Officer | ||
| (Principal<br> Financial and Accounting Officer) |
Exhibit99.6
CERTIFICATION
PURSUANTTO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS(a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
UNITEDSTATES CODE)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), the undersigned officer of BriCcell Therapeutics Corp. (the “Company”), does hereby certify with respect to the Annual Report of the Company on Form 40-F for the year ended July 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), that:
| (1) | The<br> Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|---|---|
| (2) | The<br> information contained in the Report fairly presents, in all material respects, the financial condition and results of operations<br> of the Company. |
| Date:<br> October 29, 2021 | /s/ William V. Williams |
| --- | --- |
| Dr.<br> William V. Williams | |
| Chief<br> Executive Officer |
Exhibit99.7
CERTIFICATION
PURSUANTTO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS(a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
UNITEDSTATES CODE)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), the undersigned officer of BriaCell Therapeutics Corp. (the “Company”), does hereby certify with respect to the Annual Report of the Company on Form 40-F for the year ended July 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), that:
| (1) | The<br> Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|---|---|
| (2) | The<br> information contained in the Report fairly presents, in all material respects, the financial condition and results of operations<br> of the Company. |
| Date:<br> October 28, 2021 | /s/ Gadi Levin |
| --- | --- |
| Gadi<br> Levin | |
| Chief<br> Financial Officer | |
| (Principal<br> Financial and Accounting Officer) |
Exhibit99.8
October 29, 2021
Consentof Independent Auditor
We hereby consent to the inclusion in this Annual Report on Form 40-F for the year ended July 31, 2021 of BriaCell Therapeutics Corp. (the “Company”) of our report dated October 28, 2021 relating to the consolidated financial statements of the Company as at July 31, 2021 and 2020 and for each of the three years ended July 31, 2021, 2020 and 2019 (the “Report”).
| /s/ MNP LLP |
|---|
| MNP<br> LLP |
| Mississauga,<br> Ontario, Canada |
| Chartered<br> Professional Accountants |
| Licensed<br> Public Accountants |